Piclidenoson on deck
Upcoming - detailing Cipher Pharmaceuticals least understood growth asset.
This is something I’ve been writing up for a few weeks now as I’ve been subjecting myself to a deluge of information regarding therapeutic options for moderate to severe plaque psoriasis.
For those unfamiliar, Piclidenoson is one of two primary growth catalysts inside of Cipher Pharmaceuticals growth pipeline. It’s not expected to be on the market for a few more years, so there’s relatively little in the way of coverage or guidance, and the final phase 3 in the US is ongoing. Unlike MOB-015 this product isn’t obviously a best-in-class medication for the treatment of moderate to severe plaque psoriasis, but there are a few reasons I think we could expect the drug to do well. Particularly in adolescents.
There’s also been a fairly shocking recent discovery in preclinical studies that may have opened the door to Can-fite & Cipher to treat an ultra-rare disease which currently lacks any therapeutic pharmaceutical option. I’m still on the lookout for any news or data regarding this announcement but have yet to locate any of the data. It appears an online presentation was made by a Can-Fite employee to BioJapan 2023 attendents, but no video has been located thus far.
I’ll try to have this information out as soon as I find it presentable. I look forward to sharing my research. Thank you for reading the newsletter, and especially to those of you who’ve subscribed. Your kind words and generosity have been overwhelming to say the least.
Until next time,
Left’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.